BRAF and melanoma: Indeed, recently published data suggest that for patients with actionable BRAF mutations, prioritizing treatment with ICI as first line of treatment, followed by targeting BRAF/MEK only upon disease progression leads to survival gains for this subset of melanoma patients [38,39].